Mikhail Blagosklonny is a professor of oncology and one of the authoritative voices in the field. He has dedicated most of his life and career trying to find a solution to two of the human race’s biggest medical problems: aging and cancer. To this end, he is one of the pioneering researchers in the field, and he has helped uncover potential remedies to the issues.
Mikhail Blagosklonny’s Research
Mikhail Blagosklonny attended the Pavlov State Medical University of St. Petersburg where he graduated with an M.D. in Internal Medicine and a PhD in Experimental Medicine. Today he is a professor of oncology at the Roswell Park Center Institute in New York.
Mikhail Blagosklonny is also a prolific researcher and editor. To start with, he has served as a senior scientist at Ordway Research Institute. He also publishes and edits research reports for a wide range of scientific journals including the editorial board of Death Cell and Differentiation. Much of his research has been focused on using rapamycin to treat cancer and reduce the rate of aging.
The Link between Cancer, Aging, and Target of Rapamycin (TOR)
Mikhail Blagosklonny’s research into aging and cancer has revealed that Target of Rapamycin (TOR) is a potential solution. TOR signaling pathways can be used to manipulate the cellular system’s coordination and control of aging, development, and aging. What’s more, TOR is a safer solution compared to other medications already in place. However, research is yet to be concluded as there are many external factors to consider including nutrition and psychological stress. Follow Mikhail on Loop.